Decoy Therapeutics (NASDAQ:DCOY) reported quarterly losses of $(4.18) per share which missed the analyst consensus estimate of $(4.08) by 2.45 percent. This is a 98.26 percent increase over losses of $(240.07) per share from the same period last year.